JMP Securities analyst Reni Benjamin maintained a Hold rating on LAVA Therapeutics (LVTX – Research Report) today. The company’s shares closed today at $1.29.

According to TipRanks, Benjamin is an analyst with an average return of -15.7% and a 29.92% success rate. Benjamin covers the Healthcare sector, focusing on stocks such as Blueprint Medicines, Incyte, and BeiGene.

Currently, the analyst consensus on LAVA Therapeutics is a Hold with an average price target of $1.50.

The company has a one-year high of $3.93 and a one-year low of $0.85. Currently, LAVA Therapeutics has an average volume of 434.7K.